Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term intraocular pressure changes after intravitreal aflibercept 40 mg/mL versus 114.3 mg/mL
RBR-2vmd7y7Phase 2Recruiting
- Sponsor
- Universidade Federal de Pernambuco
- Start
- Jul 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aflibercept in exudative macular degeneration and diabetic macular edema (DME) (2 arms), sponsored by Universidade Federal de Pernambuco. Primary endpoints: Intraocular pressure at 5 minutes after injection, Intraocular pressure at 30 minutes after injection and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
aflibercept
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)
Beyond the preview
Go deeper on RBR-2vmd7y7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-2vmd7y7.